embryonic ectoderm development

MAK683 hydrochloride embryonic ectodermal development (EED) inhibitor, also a potent PRC2 inhibitor, blocked cancer cell proliferation (IC50=1.014nM), with IC50 values of 59, 26, and 89 nM measured in EED Alphascreen, ELISA, and LC-MS assays, respectively.

MAK683 is an inhibitor of embryonic ectoderm development (EED) (IC50s: 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay).

EEDi-5285, an orally active and highly potent inhibitor targeting embryonic ectoderm development (EED) protein, exhibits anti-cancer activity. It demonstrates exceptional efficacy with an IC50 value of 0.2 nM, indicating robust binding affinity to the EED protein.

MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein) and, together with a VHL ligand for the E3 ubiquitin ligase, has been used to design EED-Targeted PROTACs, specifically EED degrader-1 and PROTAC EED degrader-2 [1].

EED226 is a potent, selective, and orally bioavailable embryonic ectoderm development (EED) inhibitor with an IC50 of 22 nM.

FTX-6058 is a potent orally active inhibitor targeting Embryonic Ectoderm Development (EED). It effectively induces HbF protein expression in both cell and murine models. This compound holds significant potential for researching select hemoglobinopathies such as sickle cell disease and β-thalassemia.

FTX-6058 hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED), with the ability to induce HbF protein expression in both cell and murine models. This compound is particularly valuable in the research of select hemoglobinopathies, such as sickle cell disease and β-thalassemia.

Pociredir (FTX-6058) is a potent, selective, and orally active inhibitor of embryonic ectoderm development (EED) with a KD of 0.163 nM, possessing research value in inflammatory conditions or hemoglobinopathies such as sickle cell disease (SCD).

MAK683-CH2CH2COOH, targeting embryonic ectoderm development protein (EED), alongside a VHL ligand for E3 ubiquitin ligase, contributes to the formulation of PROTAC EED degrader-1 and PROTAC EED degrader-2 [1].